This report is jointly prepared by China Association of In-Vitro Diagnostics and In Vitro Diagnostics Society of China Association for Medical Devices Industry.

According to the forecast of GHICapital, the market size of China's dPCR industry will still maintain a high growth rate from 2020 to 2024, and the market size will grow from 2.133 billion yuan to 7.011 billion yuan, at a CAGR of 34.65%.

Chinese IVD instruments market grows from RMB 10.12 billion to RMB 22.32 billion by 2020 from 2016 to 2020, at a CAGR of 21.9%. Stimulated by favorable national policies and the growing demand, it is expected to reach RMB 60.99 billion in 2025 and RMB 114.62 billion in 2030, growing at a CAGR of 22.3% and 13.4% during the periods 2020-2025 and 2025-2030, respectively.

Molecular diagnosis refers to the technique of using molecular biological methods to detect changes in the structure or expression level of genetic material in patients to make a diagnosis.

Owing to the aging population, increasing awareness of disease management, and continuous technological advancements, the global in vitro diagnostic reagents market is expected to grow from USD 69.25 billion in 2019 to USD 90.65 billion by 2023, with a CAGR of 6.2%.

In recent years, the market scale of immunodiagnostic reagents in China has been increasing year by year. In 2020, the market size of China's immunodiagnostic reagent industry reached 32.1 billion yuan, an increase of 24.42% year-on-year.

POCT industry started late in China, the overall market size is still small currently, and the penetration rate in hospitals and other terminal sites is low, so there is a huge potential development space. Qianzhan Institute predicts that from 2022-2027, the Chinese POCT market will rise by about 9% CAGR to about 18 billion yuan in 2027.

As the world's most active emerging market, the influence of China's market on the entire global scientific instrument market is rising year by year, and revenue in China has become the most important part of the global performance of many multinational companies.

On March 30 2023, Kalorama Information indicates that the global IVD market is now over $124 billion, with operations in more than 20 key healthcare and medical areas, such as infectious disease immunoassays, POC, molecular microbiology, clinical chemistry, etc.

Looking at the overall environment, the receding of the COVID-19 testing dividend, the slowdown of conventional business growth, and the pressure from the collection policy have all brought the IVD industry into an adjustment period.